Evaluation of breast cancer screening in Belgium

Luyten J, Neyt M, Camberlin C, Primus-de Jong C, Van Deynse H, Leroy R
Record ID 32018013265
English
Original Title: Update of breast cancer screening recommendations (Study 2024-11)
Authors' results and conclusions: The current organised breast cancer screening programmes are likely to offer benefits: a modest reduction in breast cancer mortality, but not in all-cause mortality. They lead to a reduction in the number of advanced cancers, particularly among women between 50 and 69 years old. Conversely, screening carries a significant risk of overdiagnosis. A substantial number of identified cancers are indolent and would never cause symptoms, ultimately subjecting patients to unwarranted interventions, financial burdens, and diminished well-being. In addition, the evidence underpinning the benefits and harms is limited and uncertain, as the seven available RCTs are outdated and characterised by methodological shortcomings. More recent observational studies are not a valid alternative, as they overestimate the benefits of the screening programme due to selection bias. The cost-effectiveness of breast cancer screening is therefore also uncertain. In a Belgian hypothetical economic evaluation, we estimated the cost-effectiveness of screening for women aged 50–69, under optimistic assumptions, at approximately €13 700 per QALY gained, but this figure rises to approximately €51 900 per QALY gained based on stricter, more reliable and likely more realistic assumptions regarding the impact on the probability of being diagnosed at an advanced stage. Other less favourable assumptions (e.g. higher rates of overdiagnosis or better survival for advanced breast cancers) make screening even less cost-effective. Consequently, the cost-effectiveness of the current screening programmes can be questioned. Extending screening to younger or older age groups appears to further reduce cost-effectiveness, due to a lower risk of breast cancer and a higher risk of overdiagnosis, respectively. Belgium does not apply a fixed ICER threshold to determine whether an intervention is cost-effective. Instead, budgetary limits play a central role: it is mainly a question of what is possible within the available budget (ability to pay), not just what one is willing to pay. The final decision also depends on other factors, such as the severity of the disease, the need for treatment, and the quality of the evidence. There is no convincing evidence that shortening the screening interval or adding ultrasound to mammography yields sufficient benefits, whilst this is certainly associated with higher costs. Therefore, there is currently insufficient justification to support these strategies based on (cost-)effectiveness.
Authors' recommendations: Preamble In Belgium, organised breast cancer screening is aimed at women aged between 50 and 69 who have not been diagnosed with breast cancer in the past 10 years, have not undergone a bilateral mastectomy and do not have a significantly increased risk of breast cancer. The recommendations below apply specifically to this target group. Therefore, they do not apply to women with a personal or family history of breast cancer, genetic risks (e.g. BRCA1 or 2) or symptoms (e.g. a lump in the breast). To the Ministers responsible for Public Health, their departments responsible for the policy and/or funding of breast cancer screening programmes, the organisations that organise, promote and/or carry out breast cancer screening, the physicians involved in this screening, the professional and scientific associations of general practitioners, gynaecologists and other relevant healthcare professionals, to health insurance funds and patient organisations: 1. Participation in breast cancer screening is a personal choice. Provide women with balanced and clear information about the evidence-based benefits and harms of breast cancer screening, as well as the uncertainties surrounding this information, to enable them to make an informed decision that aligns with their personal values and preferences. To the Ministers responsible for Public Health and their departments responsible for the policy and/or funding of breast cancer screening programmes: *With regard to the current screening programmes for women aged between 50 and 69: 2. Offer women aged between 50 and 69 who have made a personal choice to participate in breast cancer screening a mammography as part of the organised breast cancer screening programmes. This guarantees quality control and ensures that women do not have to pay a co-payment. 3. There is considerable uncertainty regarding the balance between the clinical benefits and harms of breast cancer screening, as well as regarding the cost-effectiveness of the current screening programmes. Cost-effectiveness is only plausible under a number of optimistic assumptions, the real-world validity of which is highly uncertain. Take this uncertainty into account when prioritising and allocating available resources. *With regard to a possible extension of the current breast cancer screening programmes: 4. For women under the age of 50, the balance between the clinical benefits and harms of breast cancer screening is even less certain than for the current target group. Furthermore, the incidence of breast cancer in this group is lower than in the current target group, making the programme less cost-effective. Therefore, do not extend the current screening programmes to women under the age of 50; 5. For women aged 70 and older, breast cancer screening does not reduce (breast cancer) mortality. Furthermore, there is insufficient reliable data on the harms (e.g. higher risk of overdiagnosis). Therefore, do not extend the current screening programmes to women aged 70 and older *With regard to the screening interval: 6. Currently, there are no RCT data available on the benefits and harms of annual versus biennial or triennial versus biennial breast cancer screening. For the target group, a shorter screening interval (e.g. annual screening) would result in an unfavourable balance between the number of additional breast cancers detected and the additional costs that this expansion would generate. This would result in a less favourable cost-effectiveness compared with the current biennial screening. Therefore, do not implement annual breast cancer screening. *With regard to breast cancer screening using a combination of mammography and ultrasound: 7. Breast cancer screening using a combination of mammography and ultrasound does not lead to a reduction in (breast cancer) mortality, but does result in more false-positive results. Therefore, do not extend the current mammography screening programmes with ultrasound. To the professional and scientific associations of GPs, gynaecologists and other relevant healthcare professionals, to health insurance funds and patient organisations: 8. Make additional efforts to provide women with accurate and clear information on the following: a. When women make the personal choice to participate in breast cancer screening, they should do so within the organised breast cancer screening programmes. In this regard, it is important to inform them accurately about the benefits of breast cancer screening within the organised breast cancer screening programmes, particularly the quality control of the programmes (including the double reading of every mammography and the regular training of radiologists), which is not the case with opportunistic screening, and the fact that they do not have to pay a co-payment; b. There is currently no convincing evidence that annual breast cancer screening leads to health benefits; c. The routine combination of mammography and ultrasound in breast cancer screening does not lead to a reduction in breast cancer mortality or all-cause mortality, but does result in more false-positive results and is therefore not recommended. 9. In the training of physicians, sufficient and ongoing attention should be attributed to the effects of cancer screening, as well as the correct interpretation of the results and the various sources of bias that complicate this interpretation. To the Federal Minister for Social Affairs and Public Health and the NIHDI: 10. The current invoicing codes (‘nomenclature’) do not allow differentiation between, on the one hand, mammographies and ultrasounds carried out for diagnostic purposes (e.g. women with symptoms such as a lump in the breast) and, on the other hand, mammographies and ultrasounds carried out as part of opportunistic screening. Consequently, it is not possible to assess a) the scale of opportunistic screening, and b) the quality (e.g. sensitivity and specificity). The fee schedule should therefore be revised to enable assessments to be carried out, and to allow opportunistic screening to be discontinued if the quality is found to be inadequate. To the organisations that organise, promote and/or carry out breast cancer screening, and to the physicians involved in this screening: 11. Provide women with balanced and clear information about the evidence-based benefits and harms of breast cancer screening, as well as the uncertainties surrounding this information. This will enable them to make an informed decision in line with their personal values and preferences. 12. Therefore, include a decision aid in the invitation letter and make it available to GPs, gynaecologists, radiologists and the general public, even if this would negatively affect the participation rate of the screening programmes. It is important that women are clearly informed about a) the benefits and harms (e.g. overdiagnosis) of participating in the screening, with the magnitude of both expressed in absolute numbers, and b) the potential consequences of these benefits and harms (e.g. anxiety following a false-positive screening result). This information must be understandable to people with varying levels of (health) literacy. To the Ministers responsible for Public Health and their departments responsible for the policy and/or funding of breast cancer screening programmes, the scientific associations of medical specialists involved in breast cancer screening, and scientific research institutes: 13. Develop an evidence-based decision aid to inform women in a balanced and clear manner about the benefits and harms of participating in breast cancer screening. 14. Re-evaluate the current breast cancer screening programmes as soon as the (long-term) results of the ongoing RCTs into risk-based screening become available. Based on these results, provide recommendations if this could lead to a better balance between benefits and harms and/or a more efficient use of resources. 15. Re-evaluate the current breast cancer screening programmes as soon as the (long-term) results of the ongoing RCTs into breast cancer screening for women with dense breast tissue (e.g. the DENSE2 study) become available. Based on these results, provide recommendations if this could lead to a better balance between benefits and harms and/or a more efficient use of resources. 16. There is a lack of data on the quality of life of women with breast cancer in Belgium. Therefore, we recommend that a study is set up to accurately assess this. This study should be conducted among women with breast cancer and use the EQ-5D questionnaire. It should include a sufficient number of patients within each (invasive and non-invasive) stage of breast cancer and, preferably, conduct measurements at different points in time using a longitudinal design
Details
Project Status: Completed
Year Published: 2026
URL for published report: https://doi.org/10.57598/R423C
English language abstract: An English language summary is available
Publication Type: Rapid Review
Country: Belgium
MeSH Terms
  • Breast Neoplasms
  • Mass Screening
  • Early Detection of Cancer
Keywords
  • Breast Neoplasms
  • Cost-effectiveness analysis
  • Early Detection of Cancer
  • Mammography
  • Mass Screening
  • Overdiagnosis
Contact
Organisation Name: Belgian Health Care Knowledge Centre
Contact Address: 5 Avenue Galilée, PO Box 7, 1210 Brussels. , Belgium
Contact Name: info@kce.fgov.be
Contact Email: info@kce.fgov.be
Copyright: <p>Belgian Health Care Knowledge Centre (KCE)</p>
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.